Industry Focus

Latest Episodes:

Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous? May 29, 2019

Show notes

Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.

Check out more of our content here:

CG: Between Two Fools and the Battle Brewing in Home Improvement May 28, 2019

Show notes

On this week’s episode of Industry Focus: Consumer Goods host Jason Moser and Fool.com contributor Asit Sharma take a look at the most recent quarters for The Home Depot and Lowe's and kick the tires on Canadian Tire. Plus Jason sits down with Motley Fool analyst Thomas King on a new installment of Between Two Fools!

Check out more of our content here:

Tech: Clarity on Qualcomm May 24, 2019

Show notes

Back in January, the FTC put out its antitrust case against Qualcomm and now we have Federal Judge Lucy Koh's decision. We explore the decision, what it means for Qualcomm and how it might radically change the business.

Stocks: QCOM, AAPL

Energy: Why We Love Redfin May 23, 2019

Show notes

The real estate brokerage industry hasn’t changed much in decades, with high commissions and an opaque buying process. However, Redfin is changing the industry for the better, aiming to fulfill its mission to “Redefine real estate in the consumer’s favor.”

With a powerful value proposition, capable management, and a huge addressable market, Redfin is an up-and-coming Rulebreaker that investors should be receiving investors’ attention. Motley Fool Analyst Tim Beyers and Industry Focus Host Nick Sciple, both Redfin shareholders, break down Redfin’s competitive advantages, opportunities, and risks on this week’s episode.

Stocks Mentioned: RDFN, ZG

Check out more of our content here:

Healthcare: Top Stocks To Watch at ASCO 2019 May 22, 2019

Show notes

We highlight two biotech stocks making oral presentations that could move their share price next month. Plus, Emily Flippen discusses an SEC proposal that could change reporting requirements for early stage biotechs.

Stocks: RGNX BPMC

Check out more of our content here:

CG: Luckin Takes on Starbucks; Target Sells Out May 21, 2019

Show notes

Chinese coffee company Luckin has aggressive plans to add thousands of stores and it's willing to lose a lot of money to do that. That puts it in competition with Starbucks though there might be enough customers for both. In addition Target sold out of its exclusive Vineyard Vines collection and that may not be a good thing.

Check out more of our content here:

Financials: Green Dot’s Disappointing Earnings and an Interview With Prudential’s CFO May 20, 2019

Show notes

In the latest installment of our Between Two Fools interview series, host Jason Moser sits down with Prudential (NYSE: PRU) CFO Ken Tanji to talk about financial wellness and what the company is doing to try to improve the financial wellness of Americans. Plus, Fool.com contributor Matt Frankel, CFP talks about why Green Dot (NASDAQ: GDOT) plunged after its recent earnings report, and you’ll also hear what stocks are on our radar this week. All this and more on this week’s episode of Industry Focus: Financials.

Check out more of our content here:

Tech: Checking in on IPOs May 17, 2019

Show notes

We've got our hands on the first report for recently public Pinterest! We dive in and try and figure out why the stock sold off 10% after earnings, and check in on 2018 IPOs Upwork and Docusign to see how they're faring after their first year on the market.

Check out more of our content here:

Energy: A.O. Smith, Hot Stock or in Hot Water? May 16, 2019

Show notes

If you took a hot shower this morning, there’s a good chance you got your hot water thanks to a product from A.O. Smith, America’s largest manufacturer of hot water heaters. Operating in an oligopoly market with growing demand as more of the world enters the middle class, A.O. Smith is up 9X over the last 10 years and counts itself among elite company as a dividend aristocrat. With shares down today on a recent short report from J Capital Research, Motley Fool Analyst John Rotonti joins the show to break down the investment opportunities and risks surrounding A.O. Smith today.

Stocks Mentioned: AOS

Check out more of our content here:

$50 off your first job post. Linkedin.com/fool

Healthcare: Who Had the Better Quarter, Gilead Sciences or Amgen? May 15, 2019

Show notes

It's a battle of the big bio's on this episode of Industry Focus Healthcare. Is Gilead Sciences finally overcoming its hep C headwind? Is Amgen beating back biosimilars? We dig into the details as we discuss which of these biopharma behemoths delivered better first quarter results. Stocks: GILD, AMGN

Check out more of our content here:

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected